NCT05811962 (SARCO) is a clinical trial of No intervention in Sarcoidosis, Pulmonary, sponsored by University Medical Centre Ljubljana.

Who is sponsoring NCT05811962?

NCT05811962 is sponsored by University Medical Centre Ljubljana.

What drugs are being tested in NCT05811962?

Interventions in NCT05811962: No intervention.

What condition does NCT05811962 study?

NCT05811962 studies Sarcoidosis, Pulmonary.

Is NCT05811962 still recruiting?

NCT05811962 is currently completed. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT05811962: SARCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis

Completed Last updated 13 April 2023

What this trial tests

trial testing No intervention in Sarcoidosis, Pulmonary in 135 participants. Completed in 1 December 2022.

Timeline

1 January 2014

Primary endpoint
1 August 2018

1 December 2022

Quick facts

Lead sponsor	University Medical Centre Ljubljana
Status	Completed
Study type	OBSERVATIONAL
Enrollment	135
Start date	1 January 2014
Primary completion	1 August 2018
Estimated completion	1 December 2022
Sites	1 location across Slovenia

Drugs / interventions tested

No intervention

Conditions studied

Sarcoidosis, Pulmonary — all drugs for Sarcoidosis, Pulmonary →

Sponsor

University Medical Centre Ljubljana

Who can join

18 and older, any sex, with Sarcoidosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to elucidate the role of serum amyloid A (SAA) in the diagnosis and follow-up of sarcoidosis, including its prognostic value. The main questions it aims to answer are: * Whether, at the time of diagnosis, SAA is in correlation with other serum markers of granulomatous inflammation, interstitial disease and pulmonary fibrosis, lung function and radiologic characteristics of intrathoracic sarcoidosis, * Whether increased serum concentrations of SAA at the time of diagnosis act as a prognostic marker of progressive granulomatous inflammation and pulmonary interstitial disease. Patients will undergo standard diagnostic procedures for intrathoracic sarcoidosis, according to WASOG (World association of sarcoidosis and other granulomatous disorders) criteria. Two additional vials of blood will be taken at diagnosis and one vial at follow-up for serum processing and biomarker analysis. Healthy blood donors will represent our group of healthy controls.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Correlation of the High-Resolution Computed Tomography Patterns of Intrathoracic Sarcoidosis with Serum Levels of SAA, CA 15.3, SP-D, and Other Biomarkers of Interstitial Lung Disease.
Leštan Ramovš Z, Sodin-Šemrl S, Lakota K, Čučnik S, et al · · 2023 · cited 6× · PMID 37445972 · DOI 10.3390/ijms241310794

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Sarcoidosis, Pulmonary

Currently open trials in the same condition.

NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting
NCT06479603 — RCT of Nintedanib in Fibrotic Sarcoidosis · Phase 4 · recruiting
NCT05746039 — Feasibility of Semaglutide in Advanced Lung Disease · Phase 1, PHASE2 · recruiting
NCT05291468 — the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis · NA · active not recruiting
NCT05567133 — Risk Indicators of Sarcoidosis Evolution-Unified Protocol · recruiting

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

NCT07466472 — Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity · not yet recruiting
NCT07446244 — Catheter Ablation of Advanced Forms of Atrial Fibrillation · NA · enrolling by invitation
NCT07109076 — Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton · NA · recruiting
NCT07354880 — Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease · Phase 4 · not yet recruiting
NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05811962 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Centre Ljubljana
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05811962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing